Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Spotlight
  • Published:

Imatinib sensitizes CLL lymphocytes to chlorambucil

Leukemia volume 18, pages 409–414 (2004)Cite this article

Abstract

The effect of imatinib on chlorambucil (CLB) cytotoxicity in chronic lymphocytic leukemia (CLL) lymphocytes was examined in vitro. Imatinib sensitizes the WSU and I83 human CLL cell lines, 10- and two-fold, respectively, to CLB. Furthermore, in primary cultures of malignant B-lymphocytes obtained from 12 patients with CLL (seven patients were untreated and five treated with CLB), imatinib synergistically sensitized these lymphocytes from two- to 20-fold to CLB. This synergistic effect was observed at concentrations of imatinib (⩽10 μ M), which are achievable in patients with minimal toxicity. Moreover, the combination of both drugs results in increased apoptosis in CLL cell lines. These results suggest that imatinib should be useful in improving the therapeutic index of CLB in CLL. The mechanism of action appears to involve imatinib inhibition of c-abl kinase activity with an associated decrease in CLB-induced Rad51 phosphorylation and CLB-induced Rad51 nuclear foci, suggesting that imatinib decreases Rad51-related DNA repair of CLB-induced DNA lesions. Altogether, our results suggest that imatinib is a promising adjuvant therapy to CLB treatment of CLL.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

References

  1. Panasci LC, Paiement JP, Christodoulopoulos G, Belenkov A, Malapetsa A, Aloyz R . Chlorambucil drug resistance in chronic lymphocytic leukemia: the emerging role of DNA repair. Clin Cancer Res 2001; 7: 454–461.

    CAS  PubMed  Google Scholar 

  2. Torres-Garcia SJ, Cousineau L, Caplan S, Panasci L . Correlation of resistance to nitrogen mustards in chronic lymphocytic leukemia with enhanced removal of melphalan-induced DNA cross-links. Biochem Pharmacol 1989; 38: 3122–3123.

    Article  CAS  PubMed  Google Scholar 

  3. Spanswick VJ, Craddock C, Sekhar M, Mahendra P, Shankaranarayana P, Hughes RG et al. Repair of DNA interstrand crosslinks as a mechanism of clinical resistance to melphalan in multiple myeloma. Blood 2002; 100: 224–229.

    Article  CAS  PubMed  Google Scholar 

  4. McHugh PJ, Spanswick VJ, Hartley JA . Repair of DNA interstrand crosslinks: molecular mechanisms and clinical relevance. Lancet Oncol 2001; 2: 483–490.

    Article  CAS  PubMed  Google Scholar 

  5. Blaise R, Alapetite C, Masdehors P, Merle-Beral H, Roulin C, Delic J et al. High levels of chromosome aberrations correlate with impaired in vitro radiation-induced apoptosis and DNA repair in human B-chronic lymphocytic leukemia cells. Int J Radiat Biol 2002; 78: 671–679.

    Article  CAS  PubMed  Google Scholar 

  6. Christodoulopoulus G, Malapetsa A, Schipper H, Panasci LC . Chlorambucil induction of HsRad51 in B-cell chronic lymphocytic leukemia. Clin Cancer Res 1999; 5: 2178–2184.

    Google Scholar 

  7. Bello VE, Aloyz RS, Christodoulopoulos G, Panasci LC . Homologous recombinational repair vis-à-vis chlorambucil resistance in chronic lymphocytic leukemia. Biochem Pharmacol 2002; 63: 1585–1588.

    Article  CAS  PubMed  Google Scholar 

  8. Chen G, Yuan SS, Liu W, Xu Y, Trujillo K, Song B et al. Radiation-induced assembly of Rad51 and Rad52 recombination complex requires ATM and c-Abl. J Biol Chem 1999; 274: 12748–12752.

    Article  CAS  PubMed  Google Scholar 

  9. Yuan ZM, Huang Y, Ishiko T, Kharbanda S, Weichselbaum R, Kufe D . Regulation of Rad51 function by c-Abl in response to DNA damage. J Biol Chem 1998; 273: 3799–3802.

    Article  CAS  PubMed  Google Scholar 

  10. Slupianek A, Schmutte C, Tombline G, Nieborowska-Skorska M, Hoser G, Nowicki MO et al. BCR/ABL regulates mammalian RecA homologs, resulting in drug resistance. Mol Cell 2001; 8: 795–806.

    Article  CAS  PubMed  Google Scholar 

  11. Slupianek A, Hoser G, Majsterek I, Bronisz A, Malecki M, Blasiak J et al. Fusion tyrosine kinases induce drug resistance by stimulation of homology-dependent recombination repair, prolongation of G2/M phase, and protection from apoptosis. Mol Cell Biol 2002; 22: 4189–4201.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B, Kuriyan J . Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase. Science 2002; 289: 1938–1942.

    Article  Google Scholar 

  13. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001; 344: 1038–1042.

    Article  CAS  PubMed  Google Scholar 

  14. Kantarjian HM, Cortes J, O'Brien S, Giles FJ, Albitar M, Rios MB et al. Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. Blood 2002; 99: 3547–3553.

    Article  CAS  PubMed  Google Scholar 

  15. Topaly J, Zeller WJ, Fruehauf S . Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells. Leukemia 2001; 15: 342–347.

    Article  CAS  PubMed  Google Scholar 

  16. Tipping AJ, Mahon FX, Zafirides G, Lagarde V, Goldman JM, Melo JV . Drug responses of imatinib mesylate-resistant cells: synergism of imatinib with other chemotherapeutic drugs. Leukemia 2002; 16: 2349–2357.

    Article  CAS  PubMed  Google Scholar 

  17. Deininger MW, Goldman JM, Melo JV . The molecular biology of chronic myeloid leukemia. Blood 2000; 96: 3343–3356.

    CAS  PubMed  Google Scholar 

  18. Wang JY . Regulation of cell death by the Abl tyrosine kinase. Oncogene 2000; 19: 5643–5650.

    Article  CAS  PubMed  Google Scholar 

  19. Hardin JD, Boast S, Mendelsohn M, de los Santos K, Goff SP . Transgenes encoding both type I and type IV c-abl proteins rescue the lethality of c-abl mutant mice. Oncogene 1996; 12: 2669–2677.

    CAS  PubMed  Google Scholar 

  20. Dorsch M, Goff SP . Increased sensitivity to apoptotic stimuli in c-abl-deficient progenitor B-cell lines. Proc Natl Acad Sci USA 1996; 93: 13131–13136.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Christodoulopoulos G, Muller C, Salles B, Kazmi R, Panasci L . Potentiation of chlorambucil cytotoxicity in B-cell chronic lymphocytic leukemia by inhibition of DNA-dependent protein kinase activity using wortmannin. Cancer Res 1998; 58: 1789–1792.

    CAS  PubMed  Google Scholar 

  22. Bramson J, McQuillan A, Panasci LC . DNA repair enzyme expression in chronic lymphocytic leukemia vis-à-vis nitrogen mustard drug resistance. Cancer Lett 1995; 90: 139–148.

    Article  CAS  PubMed  Google Scholar 

  23. Bramson J, McQuillan A, Aubin R, Alaoui-Jamali M, Batist G, Christodoulopoulos G et al. Nitrogen mustard drug resistant B-cell chronic lymphocytic leukemia as an in vivo model for crosslinking agent resistance. Mutant Res 1995; 336: 269–278.

    Article  CAS  Google Scholar 

  24. Mohammad RM, Mohamed AN, Hamdan MY, Vo T, Chen B, Katato K et al. Establishment of a human B-CLL xenograft model: utility as a preclinical therapeutic model. Leukemia 1996; 10: 130–137.

    CAS  PubMed  Google Scholar 

  25. Carlsson M, Sundstrom C, Bengtsson M, Totterman TH, Rosen A, Nilsson K . Interleukin 4 strongly augments or inhibits DNA synthesis and differentiation of B-type chronic lymphocytic leukemia cells depending on the costimulatory activation and progression signals. Eur J Immunol 1989; 19: 913–921.

    Article  CAS  PubMed  Google Scholar 

  26. Loignon M, Fetni R, Gordon AJ, Drobetsky EA . A p53-independent pathway for induction of p21waf1cip1 and concomitant G1 arrest in UV-irradiated human skin fibroblasts. Cancer Res 1997; 57: 3390–3394.

    CAS  PubMed  Google Scholar 

  27. Aloyz R, Xu ZY, Bello V, Bergeron J, Han FY, Yan Y et al. Regulation of cisplatin resistance and homologous recombinational repair by the TFIIH subunit XPD. Cancer Res 2002; 62: 5457–5462.

    CAS  PubMed  Google Scholar 

  28. Poot M, Schuster A, Hoehn H . Synergism between bromodeoxyuridine, bleomycin, cisplatin and chlorambucil demonstrated by a sensitive cell kinetic assay. Biochem Pharmacol 1991; 41: 1903–1909.

    Article  CAS  PubMed  Google Scholar 

  29. Brasher BB, Van Etten RA . c-Abl has high intrinsic tyrosine kinase activity that is stimulated by mutation of the Src homology 3 domain and by autophosphorylation at two distinct regulatory tyrosines. Biol Chem 2000; 275: 35631–35637.

    Article  CAS  Google Scholar 

  30. LaRosee P, O'Dwyer ME, Druker B . Insights from pre-clinical studies for new combination treatment regimens with the Bcr-Abl kinase inhibitor imatinib mesylate (Gleevec/Glivec) in chronic myelogenous leukemia: a translational perspective. Leukemia 2002; 16: 1213–1219.

    Article  CAS  Google Scholar 

  31. Gambacorti-Passerini C, Zucchetti M, Russo D, Frapolli R, Verga M, Bungaro S et al. Alpha1 acid glycoprotein binds to Imatinib (STI571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patients. Clin Cancer Res 2003, 625–632.

  32. Benson FE, Baumann P, West SC . Synergistic actions of Rad51 and Rad52 in recombination and DNA repair. Nature 1998; 391: 401–404.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported by the Leukemia Research Foundation of Canada, a fellowship to RA from the Lymphoma Foundation Canada and a generous private donation from the Helen and Nicky Rosenbloom Lang Scholarship.

Author information

Authors and Affiliations

  1. Lady Davis Institute for Medical Research, Sir Mortimer B Davis – Jewish General Hospital, Montreal, Quebec, Canada

    R Aloyz, K Grzywacz, Z-Y Xu, M Loignon, M A Alaoui-Jamali & L Panasci

Authors
  1. R Aloyz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. K Grzywacz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Z-Y Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M Loignon
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M A Alaoui-Jamali
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. L Panasci
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to L Panasci.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Aloyz, R., Grzywacz, K., Xu, ZY. et al. Imatinib sensitizes CLL lymphocytes to chlorambucil. Leukemia 18, 409–414 (2004). https://doi.org/10.1038/sj.leu.2403247

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2403247

Keywords

This article is cited by

Search

Advanced search

Quick links